Printer Friendly

Lexicon Genetics announces issuance of two key gene trapping patents.

Lexicon Genetics, Inc. (The Woodlands, TX; 281-863-3222) announced that it has been issued United States Patent 6,207,371 (the "371 patent") entitled "Indexed Library of Cells Containing Genomic Modifications and Methods of Making and Utilizing the Same." The newly-issued patent extends the scope of Lexicon's broad patent estate in the field of gene trapping, now covered by a total of four issued United States patents. The gene trapping patents complement Lexicon's gene targeting patent portfolio to provide the company with broad coverage over technologies used to efficiently determine the in vivo functions of genes and their pharmaceutical applications. Lexicon has used its gene trapping technology to discover genes having pharmaceutical product potential in the areas of cancer, cardiovascular disease, immune disorders, neurological disease, diabetes and obesity.

The 371 patent broadly covers the gene trapping technology that Lexicon has used to generate its OmniBank library of well over 100,000 gene knockout clones. Lexicon is using OmniBank to systematically discover the functions of genes uncovered by the Human Genome Project and other sequencing efforts, determining the medical importance of genes and their value for drug discovery and development based on in vivo mammalian biology. Lexicon has recently accelerated its OmniBank production and estimates that the OmniBank library now contains gene knockout clones for more than 40% of all genes in the mammalian genome.

The 371 patent also covers the gene trapping technology that Lexicon has used to discover gene sequence information from thousands of human genes. Lexicon has filed patent applications covering more than 50,000 partial human gene sequences from its gene trapping program.

Finally, the 371 patent covers collections of mutated animal cells such as the knockout mouse ES cell clones contained in Lexicon's OmniBank library, as well as Lexicon's gene trapping vectors and related methods. Lexicon also announced the earlier issuance of United States Patent 6,139,833 (the "833 patent") entitled "Targeted Gene Discovery." The 833 patent also covers elements of Lexicon's gene trapping technology.

"These patents further confirm Lexicon's leadership and ownership position in technologies for defining mammalian gene function for drug discovery," said Arthur T. Sands, M.D., Ph.D., President and Chief Executive Officer of Lexicon. "We believe that both our genome-wide gene trapping and gene-specific gene targeting technologies provide us with unique competitive advantages in translating gene discoveries into new therapeutic products."
COPYRIGHT 2001 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:Lexicon Genetics announces issuance of two key gene trapping patents.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Apr 1, 2001
Words:390
Previous Article:Evotec OAI signs screening technology agreement with Celltech.
Next Article:Avigen granted gene therapy patent for intravenous delivery of Aav vectors.
Topics:


Related Articles
Targeted Genetics licenses key gene expression technology to GTI/Systemix.
Myriad Genetics awarded United States patent for DNA sequencing.
Myriad Genetics awarded United States patent on P16 cancer protein and antibodies to protein.
Myriad Genetics awarded cancer gene patents.
Paradigm Genetics receives herbicide target patent.
Targeted Genetics obtains gene expression patent.
Targeted Genetics' obtains adeno-associated virus patent.
Lexicon patents gene trapping technology.
Lexicon Genetics broadens patent portfolio with knockout mouse patent.
Lexicon extends intellectual property portfolio with patent on gene trapping.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters